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Abstract
Background
Arteriovenous fistula (AVF) failure is a significant cause of morbidity and expense in patients
on maintenance haemodialysis (HD). Circulating biomarkers could be valuable in detecting
patients at risk of AVF failure and may identify targets to improve AVF outcome. Currently
there is little consensus on the relationship between circulating biomarkers and AVF failure.
The aim of this systematic review was to identify circulating biomarkers associated with
AVF failure.
Methods
Studies evaluating the association between circulating biomarkers and the presence or risk
of AVF failure were systematically identified from the MEDLINE, EMBASE and Cochrane
Library databases. No restrictions on the type of study were imposed. Concentrations of cir-
culating biomarkers of routine HD patients with and without AVF failure were recorded and
meta-analyses were performed on biomarkers that were assessed in three or more studies
with a composite population of at least 100 participants. Biomarker concentrations were
synthesized into inverse-variance random-effects models to calculate standardized mean
differences (SMD) and 95% confidence intervals (CI).
Results
Thirteen studies comprising a combined population of 1512 participants were included after
screening 2835 unique abstracts. These studies collectively investigated 48 biomarkers,
predominantly circulating molecules which were assessed as part of routine clinical care.
Meta-analysis was performed on twelve eligible biomarkers. No significant association
between any of the assessed biomarkers and AVF failure was observed.
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Conclusion
This paper is the first systematic review of biomarkers associated with AVF failure. Our
results suggest that blood markers currently assessed do not identify an at-risk AVF. Fur-
ther, rigorously designed studies assessing biological plausible biomarkers are needed to
clarify whether assessment of circulating markers can be of any clinical value. PROSPERO
registration number CRD42016033845.
Introduction
A surgically created arteriovenous fistula (AVF) is the preferred form of long term vascular
access (VA) for use in haemodialysis (HD) therapy. Recent statistics from the USA show that
in 2015 66% of routine HD patients used an AVF for VA, and this proportion is predicted to
increase in line with the national ‘Fistula First Catheter Last’ initiative [1]. Nevertheless, AVF
failure resulting from complications such as venous stenosis and thrombosis remain a major
cause of hospitalization and morbidity within the HD population [2]. The Dialysis Outcomes
Quality Initiative (DOQI) has reported that primary AVF failure is approximately 15% after
one year and 25% after two years [3]. Recent data suggest that AVF survival has not signifi-
cantly improved more than a decade after standardised VA guidelines were introduced [4].
Currently AVFs are monitored using duplex ultrasound (US) to assess blood flow and iden-
tify flow disturbances in the AVF or adjacent vessels. While routine screening may improve
AVF survival rates by allowing early identification and remediation of at-risk fistulae, US-
based screening programs are time and labour intensive and rely on specialist equipment
which is often unavailable at regional centres [5]. In contrast, screening programs based on the
detection of blood-borne markers (biomarkers) could provide a more cost effective means to
identify patients at risk of AVF failure.
Few studies have assessed the relationship between biomarkers and AVF failure, and dis-
crepancy exists between the conclusions reported. To date, there has been no systematic evalu-
ation of the available literature to clarify the reported association between circulating
biomarkers and AVF failure. Accordingly, we performed a systematic review and meta-analysis
of publicly available literature to examine the association of circulating biomarkers with AVF
failure.
Methods
Search protocol and study focus
We performed a systematic literature review of published work in accordance with the
MOOSE guidelines [6]. This review was registered in the PROSPERO International Registry,
registration number CRD42016033845. We sought studies that investigated the association of
at least one circulating biomarker with an AVF outcome (such as thrombosis, stenosis or fail-
ure) in patients receiving regular HD. We predominantly sought literature from the online
MEDLINE (January 1966 to December 2015), EMBASE (January 1980 to December 2015) and
the Cochrane Library databases as well as scanning reference lists of studies captured in the lit-
erature search. In performing literature searches, we applied the search terms “AVF” AND
“vascular access”, as well as one of the following title/abstract phrases: “biomarker”, “concen-
tration”, “function”, “dysfunction”, “maturation”, “patency”, “failure”, “survival”, “thrombo”,
“steno”, “factor”, “predict”, “serum”, “plasma”, “circulating”, “risk factor” and “blood” with
Circulating Biomarkers Associated with AVF Failure
PLOS ONE | DOI:10.1371/journal.pone.0159963 July 26, 2016 2 / 15
Competing Interests: The authors have declared
that no competing interests exist.
no language restriction (See S1 File for details). Titles and abstracts of identified searches were
screened and if the suitability of the article was uncertain, the full text was assessed. We consid-
ered a native AVF to mean the anastomosis of an artery and vein; and graft to mean the surgi-
cal placement of a loop or bypass (either from autologous tissue or synthetic material) to join
an artery and vein. AVF failure was defined as complications in the VA which prevented suc-
cessful HD, arising from events such as AVF stenosis or thrombosis.
Study eligibility
Studies were deemed eligible if i) the patient population investigated were using, or were to
receive a native AVF for HD; ii) the study assessed and reported the association of circulating
biomarker(s) with the presence or risk of AVF failure; iii) cases were patients with a malfunc-
tioning AVF from any reason (defined as AVF failure) and controls were patients whose AVF
remained functioning and able to be used for HD (defined as a patent AVF); iv) specific details
of the timing of blood collection relative to AVF failure were provided, and v) the full manu-
script was in English. Specific exclusion criteria included i) animal model studies; ii) studies
investigating non-surgically created AVFs; iii) non-HD related AVFs; and iv) studies evaluat-
ing multiple types of VA without providing AVF-specific results.
Quality assessment, data extraction and biomarker selection for meta-
analysis
Data extraction was performed using a standardised data extraction form (S2 File). The follow-
ing clinical data were extracted from all studies: 1) General patient characteristics (e.g. age, sex
and smoking); 2) Definitions of case and control groups; 3) Definitions of patent or failed
AVF; 4) Timing of blood sampling relative to AVF failure, and blood medium assessed; 5) Out-
come measures; 6) Methods of biomarker quantification; 7) Statistical analyses performed,
including reported concentrations, effect estimates, variability, and p-values. The type of study
design was also recorded (e.g. cohort or case control). Each study was assessed using a modified
version of the Ottawa-Newcastle tool to assess the risk of bias. The assessment tools and subse-
quent results are provided within the supplementary material (S3 and S4 Files for cohort and
case control studies, respectively). Risk of bias was classified very low, low, medium, high or
very high, depending on the assessment outcome (see S3 and S4 Files for specific details regard-
ing cohort and case control studies, respectively).
Biomarkers which were assessed by3 independent studies in a composite population of
100 patients were included in a meta-analysis. Results of the meta-analysis are presented as
mean and standard deviation (SD). Where studies presented data as mean and standard error
of the mean (SEM), standard deviation was recalculated using the following equation: SD =
SEM ×
p
n, where n = population size.
Meta-analysis
Biomarker concentrations were compared between patients with (cases), and without (con-
trols) AVF failure. An inverse-variance random-effects model was applied to determine the
standardised mean difference (SMD) and 95% confidence intervals (95% CI) of biomarker con-
centrations between case and control groups. Inter-study heterogeneity was determined using
the I2 index and its associated p-value, as detailed by detailed by Higgins et al [7]. All statistical
analyses were performed using RevMan v5.3 software (The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014) and GraphPad Prism v6.05 software. For all reported compari-
sons p-values<0.05 were considered significant.
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Results
Literature search
Initial database searches yielded 4235 potentially eligible papers for inclusion. A further nine
studies were identified from eligible reference lists (Fig 1). After removing 1409 duplicates,
2835 unique abstracts were screened. Of these, 2756 were excluded, mainly because they did
not assess a circulating biomarker, and the full text of 79 studies were assessed. Sixty six studies
were excluded after reviewing the full text, primarily due to failure to specify the timing of
blood collection relative to AVF failure. A total of thirteen studies satisfied the eligibility criteria
and were included in this review (Fig 1) [8–20].
Study characteristics and risk of bias
The characteristics of the included studies are summarised in Table 1. Nine of the studies
adopted a longitudinal cohort design (8 prospective [8, 10, 12–14, 17, 19, 20] and 1 retrospec-
tive [16]), the remaining four were cross-sectional case-control studies [9, 11, 15, 18]. Of the
thirteen studies, only three adjusted their results for the VA risk factors of age and sex [10, 16,
Fig 1. PRISMA study selection flow chart.
doi:10.1371/journal.pone.0159963.g001
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Table 1. Characteristics of the included studies.
Reference No. Patients Study
Location
Study
Design
AVF failure due
to
Method(s) of
diagnosis of AVF
failure
Time of Blood
Collection
History of AVF
functionality
AVF
Location
(Case vs
Control)
Baumann
2003 [8]
N = 62
Cases:24
Controls:38
Germany Cohort Thrombosis
within 30 days
of AVF creation
Ultrasound and/or
Surgery
Before AVF creation Newly created AVF n/r
Bilgic 2015
[9]
N = 94
Cases:51
Controls:43
Turkey Case
Control
Stenosis Ultrasound and
Fistulogram
At AVF failure Functional for at least 6
months prior to
analysis (cases and
controls)
n/r
Bojakowski
2012 [10]
N = 45
Cases:11
Controls:34
Poland Cohort Stenosis and/or
thrombosis
within 12 weeks
of AVF creation
Ultrasound and
Angiography
At AVF creation Newly created AVF.
AVF patent for 52
weeks post creation
(controls)
RC–(100%
vs 100%)
Candan
2014 [11]
N = 80
Cases:42
Controls:38
Turkey Case
Control
Thrombosis Ultrasound and/or
Fistulogram
Collected prior to a
mid-week dialysis
treatment
Newly created AVF,
functional for 3 months
prior to failure (cases).
Functional AVF for
over 3 years post
creation (controls)
n/r
Gagliardi
2011 [12]
N = 91
Cases:37
Controls:54
Italy Cohort Thrombosis Access blood flow
monitoring
Collected at monthly
intervals
Functional with no pre-
existing vascular
abnormalities (cases
and controls)
BC–(100%
vs 100%)
Jaberi 2007
[13]
N = 58
Cases:18
Controls:40
Canada Cohort Cephalic arch
stenosis
Fistulogram Variable times within
6 months of failure
diagnosis
Unclear BC–(94%
vs 70%)
Kaygin 2013
[14]
N = 386
Cases:75
Controls:311
Turkey Cohort Failure to
mature
Dialysis
complications
At AVF creation AVF failure within first
12 weeks (cases). AVF
patent at end of 12
weeks (control)
RC–(59%
vs 69%)
BC–(41%
vs 30%)
Kim 2013
[15]
N = 64
Cases:34
Controls:30
Korea Case
Control
Stenosis Ultrasound Prior to midweek
dialysis at monthly
intervals for a total of
6 months
Functional with no pre-
existing abnormalities
for at least 6 months
(cases and controls)
RC–(100%
vs 100%)
Kirkpantur
2008 [16]
N = 99
Cases:38
Controls:61
Turkey Cohort Thrombosis Dialysis
complicationsand
Angiography
At AVF creation plus
fasting monthly pre-
HD collections up to
failure (cases) or
end of follow up
(controls)
AVF were patent for at
least 6 weeks following
surgical opening of
AVF (cases and
controls)
RC–(76%
vs 77%)
BC–(24%
vs 21%)
Masaki
1999 [17]
N = 184
Cases:83
Controls:101
Japan Cohort Stenosis or
Thrombosis
Surgery and/or
Radiography and/or
Ultrasound
At AVF failure
(cases), unspecified
for controls
n/r n/r
Ozdemir
2005 [18]
N = 141
Cases:60
Controls:81
Turkey Case
Control
Thrombosis n/r 6 months prior to
AVF thrombosis
(cases) or 6 months
prior to study
(controls)
One or more
thromboses (cases).
No recorded
thromboses (controls)
SB–(30.8%
vs 4.9%)
Wu 2009
[19]
N = 100
Cases:41
Controls:59
China Cohort Restenosis
following PTA
Fistulography Immediately before
PTA (cases) or
routine HD (controls)
All patients had history
of stenosis (cases and
controls) and
underwent PTA
n/r
Yilmaz 2014
[20]
N = 108
Cases:64
Controls:44
Turkey Cohort Stenosis Ultrasound and
Angiography
Measured 6 months
prior to stenosis
diagnosis
Functional for at least 6
months prior to
analysis (cases and
controls)
n/r
AVF: arteriovenous fistula; n/r: not recorded; HD: haemodialysis; RC: radiocephalic AVF; BC: brachiocephalic AVF. SB: Snuffbox AVF; PTA: percutaneous
transluminal angioplasty. Studies by Baumann et al. and Masaki et al. were not included in the meta-analysis as neither study presented the mean
concentration of measured biomarker(s) within the text.
doi:10.1371/journal.pone.0159963.t001
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19]. Only five studies collected blood samples for biomarker measurement at a time considered
appropriate to the primary outcome assessed, i.e. for studies assessing the future risk of AVF com-
plications, blood collection within one week of AVF creation was deemed appropriate, and for
studies assessing biomarkers associated with the presence of an AVF complication, blood collection
within one week of the time of AVF failure [8–10, 14, 19]. All but four studies included an AVF
population representative of the general HD population (e.g. excluded co-morbidities such as active
infection) [8, 12, 18, 19], and only one failed to provide clear patient selection criteria [17].
Using the modified Ottawa-Newcastle tool to assess the risk of bias in the nine cohort stud-
ies (S3 File) we found one with a very low risk [10], 3 studies with a low risk [8, 12, 14], 2 stud-
ies with a medium risk [16, 17] and the final 3 with a high risk of bias [13, 19, 20]. Of the case
control studies, 2 were considered low risk [9, 11] and 2 were considered medium risk [15, 18]
of bias (S4 File).
The combined population of the thirteen studies totalled 1512 participants, including 578
cases and 934 controls. Total sample size ranged from 45 to 386 patients [10, 14]. The median
number of cases per study was 40 (range 11 to 83), with a median age of 57 years (range 45 to
68) and comprising a median 55.8% males (range 36.6 to 65.2). The median number of controls
per study was 44 (range 30 to 311), with a median age of 55 years (range 41 to 62) and compris-
ing a median 56.7% males (range 45.8 to 70.6).
All studies, excluding that of Baumann et al, and Masaki et al., listed mean biomarker con-
centrations for groups of patients with failed (cases) or patent (controls) AVFs [8, 17]. The
study by Bojakowski et al. compared groups of patients who had early fistula failure (12 weeks
post AVF creation), late fistula failure (52 weeks post AVF creation) or no fistula failure [10].
For the purposes of this review, patients with early fistula failure were considered to be the
cases as failure occurred closer to the time of blood collection (at time of AVF creation), and
patients with late AVF failure were excluded [10]. Five studies included only patients with a
newly formed fistula in anticipation of HD [8, 10, 11, 14, 16], while the remaining studies
included only patients receiving routine HD [9, 12, 13, 15, 17–20]. In all but one study, control
patients included in this review had an AVF that was patent for at least 6 months. In contrast,
all patients included in the study by Wu et al., had received a percutaneous transluminal angio-
plasty (PTA) to resolve a previous AVF dysfunction and controls were considered those
patients who did not experience restenosis following this procedure [19].
Reported biomarkers and AVF failure
We observed considerable inter-study variation in the definition of AVF failure. For the pur-
pose of this meta-analysis we initially included all outcomes reported (stenosis, thrombosis and
AVF dysfunction arising from unknown complications which led to HD complications) as
AVF failure (Table 1). Six studies investigated the association of circulating biomarkers with
AVF stenosis or restenosis [9, 13, 15, 16, 19, 20] four studies with AVF thrombosis [8, 11, 12,
18], two with a mixture of both AVF stenosis and thrombosis [10, 17], and one study did not
specify the cause of AVF dysfunction [14]. There was considerable disparity in the timing of
blood sample collection relative to AVF failure between studies (Table 1). Three studies pro-
vided mean biomarker values over time, often including samples taken at the time of AVF crea-
tion, as well as samples leading up to and including AVF dysfunction [12, 15, 16]. Three
studies analysed blood samples before or at the time of fistula creation only [8, 10, 15], and
four at the time of AVF failure only [9, 11, 17, 19]. The final three studies collected blood sam-
ples within the 6 months prior to AVF failure [13, 18, 20]. Most studies lacked specific details
of the methods of biomarker measurement, with many stating quantification was achieved by
an “automated analyser” (S1 Table). Furthermore it was not well reported whether biomarkers
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were measured in plasma, serum or whole blood (S1 Table). For the purpose of the meta-analy-
sis, biomarker data from only 11 of the thirteen studies were included as Baumann et al and
Masaki et al did not provide mean biomarker concentrations for patients that did and did not
have AVF failure [8, 17].
Comparison of biomarker concentrations in cases and controls
All biomarkers assessed in the reviewed studies are shown in S1 Table. Out of the 48 measured
biomarkers, 12 (albumin, creatinine, C-reactive protein (CRP), calcium, ferritin, haemoglobin,
high-density lipoprotein (HDL-C) cholesterol, low-density lipoprotein (LDL-C) cholesterol,
parathyroid hormone, phosphorus, total cholesterol (TC) and triglycerides (Table 2)) satisfied
the inclusion criteria for the current meta-analysis. The number of studies assessing each bio-
marker varied from 10 studies (albumin) to three studies (creatinine). Mean concentrations of
the biomarkers in case and control groups reported by each study are listed in Table 3. There
was considerable intra- and inter-study variation in the number of decimal places reported for
each biomarker concentration and thus all biomarkers are listed to the decimal point as origi-
nally published. Further, for all but one paper (Jaberi et al., [13]), biomarker concentrations
were reported in United States standard (US) units and so to avoid decimal point rounding
errors, the subsequent meta-analyses were performed using the concentrations reported in US
units. Data from Jaberi et al., was converted from International Standard (SI) units into US
units for inclusion into the meta-analysis [13]. For the purpose of clarity, biomarker concentra-
tions are presented in both US and SI units in Table 3. It is important to note that due to the
often interchangeable use of the term phosphorus and phosphate between studies, data relating
to either terminology were included in the meta-analysis denoted here as ‘phosphorus’ [21].
Meta-analysis findings
The association of biomarkers with all AVF failure. The association of the eligible 12
biomarkers with AVF failure was assessed using an inverse-variance random-effects model.
None of the twelve biomarkers were found to be significantly associated with AVF failure
when we included all measured outcomes of AVF failure (Table 4, S1 Fig). A leave-one-out sen-
sitivity analysis was performed for each of the twelve biomarkers (S5 File). Only the exclusion
of the data by Kirkpantur et al. led to statistically significant inverse associations of elevated
Table 2. Biomarkers for whichmeta-analyses were performed.
Biomarker No. of studies References Total population
Albumin 10 9–16, 19, 20 1125
Calcium 5 9, 13, 15, 19, 20 424
Creatinine 3 10, 14, 19 531
CRP 9 9–12, 14, 15, 18–20 1109
Ferritin 5 9–11, 18, 20 468
Haemoglobin 6 9–11, 13, 16, 20 484
HDL-C 7 9–11, 14, 16, 19, 20 912
LDL-C 7 9–11, 14, 16, 19, 20 912
PTH 4 9, 11, 18, 20 423
Phosphorus 5 9, 13, 15, 19, 20 424
Total cholesterol 4 11, 12, 14, 16 656
Triglycerides 7 9–11, 14, 16, 19, 20 912
CRP: C-reactive peptide; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; PTH: Parathyroid hormone.
doi:10.1371/journal.pone.0159963.t002
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Table 3. Biomarker concentrations in patients with (case) and without (control) AVF failure
Marker US units (SI units) ref Cases Controls p
n Mean SD n Mean SD
Albumin g/dL (g/L) 9 51 3.87 (38.7) 0.36 (3.6) 43 3.91 (39.1) 0.42 (4.2) 0.189
10 11 3.2 (32) 1.1 (11) 34 4.0 (40) 0.4 (4) dns
11 42 3.8 (38) 0.3 (3) 38 3.8 (38) 0.3 (3) 0.924
12 37 3.26 (32.6) 0.40 (4.0) 54 3.49 (34.9) 0.46 (4.6) 0.018
13 18 3.4 (34) 0.4 (4) 40 3.3 (33) 0.4 (4) n/r
14 75 3.0 (30) 0.8 (8) 311 3.96 (39.6) 0.4 (4) <0.001
15 34 3.8 (38) 3.5 (35) 30 3.9 (39) 2.2 (22) 0.761
16 38 3.67 (36.7) 0.26 (2.6) 61 3.95 (39.5) 0.39 (3.9) 0.010
191 41 3.59 (35.9) 0.44 (4.4) 59 3.63 (36.3) 0.43 (4.3) 0.64
20 64 3.76 (37.6) 0.68 (6.8) 44 3.73 (37.3) 0.56 (5.6) 0.005
Calcium mg/dL (mmol/L) 9 51 8.40 (2.10) 0.52 (0.13) 43 8.50 (2.13) 0.65 (0.16) 0.231
13 18 9.16 (2.29) 0.60 (0.15) 40 9.08 (2.27) 0.72 (0.18) n/r
15 34 8.5 (2.1) 4.1 (1.0) 30 8.6 (2.2) 2.7 (0.7) 0.719
19 41 9.97 (2.49) 1.04 (0.26) 59 9.89 (2.47) 0.86 (0.21) 0.66
20 64 8.02 (2.00) 0.64 (0.16) 44 8.10 (2.02) 0.55 (0.14) 0.422
Creatinine mg/dL (μmol/L) 10 11 5.2 (459.7) 1.9 (168.0) 34 5.1 (450.8) 1.9 (168.0) dns
14 75 4.2 (371.3) 2.6 (229.8) 311 4.1 (362.4) 2.5 (221.0) 0.597
19 41 10.60 (937.04) 2.20 (194.48) 59 10.20 (901.68) 2.20 (194.48) 0.34
CRPmg/L (nmol/L) 9 51 18.77 (178.77) 20.48 (195.05) 43 13.28 (126.48) 12.47 (118.76) 0.271
10 11 18.6 (177.15) 16.8 (160.0) 34 7.3 (69.5) 6.6 (62.9) dns
11 42 12.6 (120.0) 16.6 (158.1) 38 12.4 (118.1) 16.3 (155.24) 0.940
122 37 11.98 (114.10) 9.1 (86.7) 54 9.83 (93.62) 11.4 (108.6) 0.341
14 75 18.6 (177.2) 4.3 (41.0) 311 4.6 (43.8) 2.2 (21.0) <0.001
15 34 3.8 (36.2) 13.4 (127.6) 30 4.0 (38.1) 15.3 (145.72) 0.479
18 60 12.9 (122.9) 15.0 (142.9) 81 11.2 (106.7) 11.4 (108.6) n/r
19 41 7.3 (69.5) 9.1 (86.7) 59 8.8 (83.8) 10.0 (95.2) 0.44
20 64 9.75 (92.86) 11.97 (114.00) 44 8.94 (85.1) 12.3 (117.2) 0.502
Ferritin ng/mL (pmol/L) 9 51 422.4 (949.1) 240.8 (541.1) 43 439.1 (986.7) 230.7 (518.4) 0.346
10 11 170.4 (382.9) 104.7 (235.3) 34 235.7 (529.6) 314.5 (706.7) dns
11 42 855.1 (1921.4) 714.9 (1606.4) 38 890.6 (2001.2) 619.1 (1391.1) 0.814
18 60 552.4 (1241.2) 821.6 (1846.1) 81 497.6 (1118.1) 308.4 (693.0) n/r
20 64 542.43 (1218.77) 230.45 (517.8) 44 539.15 (1211.47) 286.37 (643.47) 0.657
Hb g/dL (g/L) 9 51 10.85 (108.5) 1.15 (11.5) 43 10.90 (109.0) 1.26 (12.6) 0.542
10 11 9.7 (97) 1.0 (10) 34 10.9 (109) 1.5 (15) dns
11 42 11.6 (116) 1.5 (15) 38 11.3 (113) 1.3 (13) 0.266
13 18 11.6 (116) 1.5 (15) 40 11.6 (116) 1.3 (13) n/r
16 38 10.9 (109) 1.0 (10) 61 11.2 (112) 1.0 (10) 0.080
20 64 10.83 (108.3) 1.97 (19.7) 44 10.75 (107.5) 1.82 (18.2) 0.848
HDL-C mg/dL (mmol/L) 9 51 39.6 (1.0) 10.3 (0.3) 43 38.7 (1.0) 11.2 (0.3) 0.305
10 11 52.1 (1.4) 18.5 (0.5) 34 56.7 (1.5) 17.6 (0.5) dns
11 42 33.9 (0.9) 13 (0.3) 38 32.4 (0.8) 8.9 (0.2) 0.552
14 75 42.8 (1.1) 12.5 (0.32) 311 39.6 (1.0) 11.8 (0.3) n/r
16 38 31.4 (0.8) 4.4 (0.1) 61 44 (1.1) 7 (0.2) 0.015
19 41 54 (1.4) 19 (0.5) 59 50 (1.3) 17 (0.4) 0.24
20 64 31.8 (0.8) 12.6 (0.3) 44 51.5 (1.3) 11.9 (0.3) <0.001
(Continued)
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LDL-C and TC with AVF failure (p = 0.02 and p = 0.007 respectively) [16]. High I2 values were
observed for most meta-analyses when including all eligible studies (Table 4), with little change
observed during most of the leave-one-out analyses (S5 File).
The association of biomarkers with AVF thrombosis or stenosis. Sub-analyses were
conducted to specifically assess the association of biomarkers with AVF stenosis/restenosis [9,
Table 3. (Continued)
Marker US units (SI units) ref Cases Controls p
n Mean SD n Mean SD
LDL-C mg/dL (mmol/L) 9 51 154.5 (4.0) 32.6 (0.8) 43 128.7 (3.3) 28.6 (0.74) <0.001
10 11 108.6 (2.8) 48.1 (1.3) 34 99.5 (2.6) 45.7 (1.2) dns
11 42 98 (2.5) 35.1 (0.9) 38 95.9 (2.5) 33 (0.9) 0.784
14 75 118.7 (3.1) 28.6 (0.7) 311 114.8 (3.0) 28.3 (0.7) n/r
16 38 62.8 (1.6) 11.0 (0.3) 61 97.4 (2.5) 19 (0.5) 0.022
19 41 113 (2.9) 33 (0.9) 59 102 (2.6) 30 (0.8) 0.09
20 64 102.69 (2.66) 36.13 (0.94) 44 99.86 (2.59) 39.49 (1.02) 0.378
PTH pg/mL (= ng/L) 9 51 332.8 160.5 43 319.5 204.3 0.105
113 42 267.5 229.5 38 311.4 316.1 0.477
18 60 449.4 363.4 81 492.0 409.9 n/r
20 64 371.70 301.04 44 361.57 327.48 0.815
Phosphorus mg/dL (mmol/L) 9 51 5.80 (1.87) 1.90 (0.61) 43 5.75 (1.86) 1.79 (0.58) 0.365
134 18 6.25 (2.02) 2.20 (0.71) 40 5.14 (1.66) 1.46 (0.47) n/r
15 34 5.3 (1.7) 26.2 (8.46) 30 5.2 (1.7) 26.8 (8.7) 0.813
194 41 4.39 (1.42) 1.36 (0.44) 59 4.45 (1.44) 1.74 (0.56) 0.84
20 64 6.29 (2.03) 1.51 (0.49) 44 6.13 (1.98) 1.49 (0.48) 0.375
TC mg/dL (mmol/L) 11 42 167 (4.3) 45.3 (1.2) 38 160.7 (4.2) 43.7 (1.1) 0.544
12 37 148.24 (3.84) 23.50 (0.61) 54 136.00 (3.52) 35.60 (0.92) 0.069
14 75 183.5 (4.8) 28.2 (0.7) 311 172.3 (4.5) 44.9 (1.2) n/r
16 38 145.6 (3.8) 35.1 (0.9) 61 155 (4) 34.5 (0.9) 0.860
TG mg/dL (mmol/L) 9 51 279.5 (3.2) 90.4 (1.0) 43 288.9 (3.3) 106.6 (1.2) 0.411
10 11 158.4 (1.8) 75.8 (0.9) 34 148.6 (1.7) 82.4 (0.9) dns
11 42 181.8 (2.1) 84.7 (1.0) 38 170.1 (1.9) 84.7 (1.0) 0.891
14 75 148.6 (1.7) 74.8 (0.9) 311 153.8 (1.7) 82.2 (0.9) n/r
16 38 143.6 (1.6) 66.2 (0.8) 61 161.3 (1.8) 61.5 (0.7) 0.390
19 41 175 (2.0) 105 (1.2) 59 155 (1.8) 80 (0.9) 0.27
20 64 195.58 (2.2) 89.41 (1.0) 44 198.78 (2.3) 96.436 (1.09) 0.865
CRP: C-reactive peptide; Hb: Haemoglobin; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; PTH: Parathyroid
hormone; TC: Total cholesterol; TG: Triglycerides. There was considerable inter and intra-study variability in the number of decimal places reported for each
biomarker observed and to avoid ambiguity, data are shown exactly as reported by the original studies. Biomarker concentrations are reported in both US
and SI units (the latter in parentheses). P-values reported as published, those in bold are considered significant. Those p-values not reported denoted as n/r,
those p-values not reported due to ANOVA analyses denoted as dns (did not specify). n = patient number; SD: standard deviation; AVF: arteriovenous
fistula. Gagliardi et al [12] and Kaygin et al [14] did not specify SD or standard error of the mean (SEM), however based on reported p-values it was assumed
to be SD. Kim et al [15] reported SEM, therefore SD was manually calculated using the formula: SD ¼ SEM ffiffiffinp : 1Values reported by [19] as mg/dL,
however this would make the albumin values 1000-fold different from the other reported values, therefore assumed to be g/dL. 2Values reported by [12] as
ng/mL, however this would make the CRP values 1000-fold different from the other reported values, therefore assumed to be mg/L. 3Values reported by [11]
as pg/dL, however this would make the PTH values 100-fold different from the other reported values, therefore assumed to be pg/mL. 4Values reported by
[13] and [19] are reported as phosphate measurements, however the terms phosphorus and phosphate are often interchangeably used in clinical reports
[21] and therefore all measurements were considered to be phosphorus.
doi:10.1371/journal.pone.0159963.t003
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13, 15, 16, 19, 20] or AVF thrombosis (Table 1) [11, 12, 18]. The study by Kaygin et al, was not
clear in its definition of AVF failure [14], and was therefore excluded from these analyses. In
line with the inclusion criteria for meta-analysis (assessed in at least 3 studies and100 partici-
pants), albumin and CRP were the only 2 biomarkers which could be assessed in these sub-
analyses (Fig 2). No significant association of either of these markers with AVF stenosis or
thrombosis was observed. It was noted that the cases reported by Bojakowski et al. included a
mixture of patients with failed AV due to either thrombosis or stenosis [10]. To eliminate
potential confounding from this mixed population, meta-analyses assessing the association of
albumin and CRP with AVF stenosis, and CRP with AVF thrombosis were repeated, excluding
data from Bojakowski et al. [10]. No association of these markers with either AVF outcome
was observed (Table 5). We were unable to assess the association of albumin with AVF throm-
bosis as only 2 studies remained after excluding data from Bojakowski and colleagues which
violated inclusion criteria for the current study. A leave-one-out sensitivity analysis was also
performed for each biomarker (S5 File).
Table 4. Meta-analysis of biomarker data in relation to AVF failure.
Biomarker Studies NCases NControls SMD (95%CI) p value* I2 I2 p value
Albumin 10 411 714 -0.44 [-0.95, 0.07] 0.09 93% < 0.001
Calcium 5 208 216 -0.04 [-0.24, 0.15] 0.67 0% 0.86
Creatinine 3 127 404 0.08 [-0.13, 0.28] 0.46 0% 0.84
CRP 9 415 694 0.75 [-0.32, 1.82] 0.17 98% < 0.001
Ferritin 5 228 240 -0.01 [-0.19, 0.18] 0.92 0% 0.92
Haemoglobin 6 224 260 -0.10 [-0.33, 0.14] 0.42 36% 0.17
HDL-C 7 322 590 -0.45 [-1.12, 0.23] 0.20 95% < 0.001
LDL-C 7 322 590 -0.06 [-0.64, 0.53] 0.85 93% < 0.001
PTH 4 217 206 -0.04 [-0.23, 0.15] 0.67 0% 0.83
Phosphorus 5 208 216 0.10 [-0.10, 0.30] 0.32 4% 0.39
TC 4 192 464 0.14 [-0.12, 0.41] 0.28 50% 0.11
TG 7 322 590 -0.02 [-0.17, 0.12] 0.74 0% 0.70
SMD: standardised mean difference; I2: heterogeneity index; NCases: Number of patients with a failed AVF; NControls: Number of patients with a patent AVF;
CRP: C-reactive protein; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; PTH: Parathyroid hormone; TC: Total
cholesterol; TG: Triglycerides. P-values in bold are significant.
*Calculated according to inverse-variance random-effects model
doi:10.1371/journal.pone.0159963.t004
Fig 2. Circulating levels of albumin or CRP are not significantly associated with either AVF stenosis or AVF thrombosis in HD patients. Forest plot
of meta-analysis data showing the association between circulating albumin with AVF (a) stenosis or (b) thrombosis; and circulating CRP with AVF (c)
stenosis or (d) thrombosis.
doi:10.1371/journal.pone.0159963.g002
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Discussion
Main Findings
AVF failure is a significant cause of morbidity and expense in the HD population [2]. Older
age, female sex, diabetes, and smaller vein calibre are established risk factors for AVF failure
[22]. No comprehensive assessment of the association between circulating biochemical factors
and AVF failure has been previously published. We analysed data from thirteen studies and
included twelve biomarkers in a meta-analysis from a possible group of 48 [8–20]. There was
no significant association between any of these 12 biomarkers with AVF failure due to any
cause, or when AVF failure was specifically due to stenosis or thrombosis. A possible reason
for this result is study heterogeneity, evidenced by high I2 statistic and significant I2 p-value in
many analyses.
Sources of Heterogeneity
The studies included in this review varied in many aspects. One such variation is differences
between the methods used to measure biomarker concentrations. Most studies failed to provide
comprehensive details on laboratory methods and the medium in which biomarkers were
quantified (e.g. plasma or serum), and for those that did provide this information, blood
medium varied considerably between studies. Differences in methodology have also previously
been acknowledged to generate heterogeneity of biomarker concentrations in other studies [19,
23]. Another source of heterogeneity is the timing in which blood samples were collected in
relation to AVF assessment. Of the eleven studies included in the meta-analyses, only three
clearly stated that blood collection occurred at the time of AVF failure [9, 11, 19]. The remain-
der took a single measurement at AVF creation [10, 14], a single measurement while the AVF
was functional [18, 20], or collected several blood samples to generate a mean over time [12,
13, 15, 16]. These methods could potentially either precede biochemical changes associated
with AVF failure or combine circulating biochemical parameters associated with patent AVFs
with those of failing AVFs, thereby dampening any possible association. Thus few of the studies
were appropriately designed to identify circulating markers of AVF failure.
The primary outcome assessed also varied amongst the included studies. For example,
Gagliardi et al. investigated factors that influenced AVF failure due to thrombosis, whereas
Jaberi et al investigated the factors influencing cephalic arch stenosis [12, 13]. Whilst both stud-
ies presented results in a way that allowed an association to be drawn between a biomarker and
Table 5. Meta-analysis of the association of albumin and CRPwith AVF stenosis and thrombosis.
AVF Outcome Biomarker Studies NCases NControls SMD (95%CI) p value* I2 I2 p-value
Stenosis Albumin 7 257 311 -0.24 [-0.57, 0.08] 0.14 71% 0.002
Albumin† 6 246 277 -0.14 [-0.42, 0.15] 0.34 60% 0.03
CRP 5 201 210 0.19 [-0.14, 0.52] 0.26 61% 0.04
CRP† 4 190 176 0.06 [-0.15, 0.26] 0.59 0% 0.44
Thrombosis Albumin 3 90 126 -0.53 [-1.14, 0.08] 0.09 77% 0.01
CRP 4 150 207 0.27 [-0.08, 0.62] 0.13 57% 0.07
CRP† 3 139 173 0.12 [-0.10, 0.34] 0.30 0% 0.83
SMD: standardised mean difference; I2: heterogeneity index; CRP: C-reactive protein; NCases: Number of patients with a failed AVF; NControls: Number of
patients with a patent AVF
*Calculated according to inverse-variance random-effects model
†Analysis excluded mixed population data from Bojakowski et al. P-values in bold are significant.
doi:10.1371/journal.pone.0159963.t005
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AVF outcome, in reality the two populations themselves represent significantly different
cohorts.
In an attempt to overcome limitations of inter-study heterogeneity, sub analyses were con-
ducted to assess the association of biomarkers with AVF stenosis or AVF thrombosis specifi-
cally. Due to our meta-analysis inclusion criteria this analysis was limited to albumin and CRP.
There was no statistically significant association found between either albumin or CRP with
AVF stenosis or thrombosis. These sub-analyses are likely underpowered although heterogene-
ity appeared to be reduced since the I2 statistics were lower than for analyses of all studies.
The location of the AVF differed between studies, although most investigations focussed on
brachiocephalic or radiocephalic fistulae. Brachiocephalic fistulae are reported to have greater
patency, although they are also associated with a greater incidence of complications, particularly
steal syndrome [24–26]. Most studies provided little information on the follow-up time, length of
time patients were on HD prior to the study, history of previous AVF events, prevalence of diabe-
tes and medication usage, which are important determinants of AVF outcome [27]. Overall the
identified studies failed to report important and well defined determinants of AVF outcome. The
quality of clinical research performed in this area may be greatly improved by standardised defi-
nitions of parameters that should be included in such studies in order to guide future work.
Future Directions
Six potentially important biomarkers were not included in this study as they did not fulfil the
specified inclusion criteria. Elevated fibrinogen has been reported to be significantly associated
with AVF failure [14], although this is contradicted by another study where no association was
found between fibrinogen and AVF failure [12]. Red blood cell distribution width (RDW), an
indicator of anisocytosis, was reported to be significantly greater in patients with AVF failure
in a single study [10]. Elevated RDW is also associated with other cardiovascular conditions
such as coronary artery disease and myocardial infarction [28, 29], suggesting that increased
RDW alone is unlikely to be specific to AVF failure. Plasma asymmetrical dimethylarginine
(ADMA), an endogenous inhibitor of nitric oxide synthase, has also reported to be higher in
patients with restenosis following a PTA, than patients whose AVF remained patent following
the procedure [19]. Similarly, elevated levels of serum osteoprotegerin (OPG) have been
reported to predict AVF stenosis [15], possibly linked to the histopathological similarities
between AVF stenosis and atherosclerosis [12]. Soluble endothelial leukocyte adhesion mole-
cule-1 (sE-selectin) has also been reported to be significantly elevated in patients with AVF ste-
nosis [9]. E-selectin has been previously implicated in intimal hyperplasia [9]. Finally,
significantly lower levels of the angiogenic cytokine vascular endothelial growth factor A
(VEGF-A) were reported in patients with AVF thrombosis [11]. VEGF-A has been shown in
animal models to have an anti-thrombotic effect and therefore may be a valuable prognostic
tool [11]. Additional studies will be needed to conclusively establish the relationship between
AVF functionality and these six biomarkers, however these data provide new directions for
pathophysiological investigations into the failing AVF.
Study Limitations
This review had a number of limitations. Firstly, few data have been published in this field and
thus sample sizes in our meta-analyses were small, reducing our analytical power. We set our
eligibility for meta-analysis at biomarkers assessed in3 studies with a total population of
100 participants, which we felt was a minimum requirement for such an analysis. As such we
have excluded some biomarkers from the meta-analysis. Consequently, this also limited our
ability to perform sub-analyses with regards to a specific cause of AVF failure (e.g. AVF
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stenosis or thrombosis) for all biomarkers assessed in this meta-analysis. It is plausible that ana-
lysing a composite outcome (all AVF failure) may mask the effect of biomarkers on a specific
cause of AVF failure. Secondly, there was significant heterogeneity between the studies, impact-
ing on the strength of findings in the meta-analyses. Thirdly, AVF is just one form of VA and as
such we have excluded a large proportion of studies that investigated the outcome of arteriove-
nous grafts and other forms of VA. However, an AVF is generally recognised as the superior
form of VA and this was a motivating factor in our study design. Fourthly, we obtained data
from publically available literature and therefore did not have access to primary data. In instances
where data were unavailable, authors were contacted to obtain relevant data. We cannot exclude
the potential influence of publication bias on our findings. Finally, we were limited to searching
for articles published in the English language, and it is therefore possible that potentially useful
papers detailing other markers of AVF failure in non-English journals were not included here.
We acknowledge this as a potential source of bias in the findings of our analysis.
Conclusion
To our knowledge this meta-analysis represents the first comprehensive investigation of bio-
markers associated with AVF failure. Our results demonstrate no conclusive association of any
previously assessed biomarker with AVF failure, although it is important to note that the range
of evaluated biomarkers is narrow and predominantly restricted to markers assessed in routine
clinical investigations. We conclude that rigorously designed studies of biologically plausible
biomarkers are needed to decide the clinical value of biomarkers for monitoring HD. Care
must be taken during experimental design, to ensure study protocol effectively addresses the
primary research question. For example, in investigations designed to correlate biomarkers
with AVF failure, blood samples must be taken appropriate to the time of failure.
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